Skip to content

Cerus CERS Other Income (Expense)

Other Income (Expense) at other companies

Haemonetics logo
HaemoneticsHAE
-$5.37M-799%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$24.2M-34.9%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$53K-35.4%
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
$3.4M+343%
ADMA Biologics logo
ADMA BiologicsADMA
-$1.15M+19.8%

Other financials

Income statement

See full
Revenue$53.7M+24.1%
Operating income-$354.0K+94.0%
Net income-$1.6M+78.7%
EPS (diluted)-$0.01+75.0%

Balance sheet

See full
Cash & equivalents$27.9M+43.0%
Total debt$45.0M-43.3%
Total equity$67.6M+21.7%
Total assets$222.9M+7.8%

Cash flow

See full
Operating cash flow-$3.0M-261%
CapEx$233.0K+108%
Free cash flow-$3.3M-243%

Valuation

See full
Market cap$573.06M+124%
Enterprise value$590.17M+86.7%
P/S2.9×-1.0×

Profitability

See full
Gross margin64%
Operating margin-6.2%-2.1pp
Net margin-9.8%-2.8pp
FCF margin3.5%+1.9pp

Returns & leverage

See full
Return on equity-15.5%-5.6pp
Debt / equity0.7×-0.8×
Current ratio1.6×-0.7×

Where this comes from

Reported directly by Cerus in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The official record: Cerus’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cerus's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cerus's other income (expense)?
Cerus (CERS) reported other income (expense) of -$1.2M in Q1 2026.
How has Cerus's other income (expense) changed year-over-year?
Cerus's other income (expense) increased by 32.8% year-over-year, from -$1.79M to -$1.2M.
What is the long-term trend for Cerus's other income (expense)?
Over 4 years (2021 to 2025), Cerus's other income (expense) has grown at a 6.6% compound annual growth rate (CAGR), from -$5.12M to -$6.6M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.